Self-Reported Patient's Continuation Rate, Complications, and Content (3c's Study) with Levonorgestrel Intrauterine System (LNG-IUS) for Heavy Menstrual Bleeding

Background Heavy menstrual bleeding (HMB) affects up to one-third of women, who experience HMB at some point in their lifetime, which impacts a woman's quality of life, physically, emotionally, and socially. Aiming that treatment and management options should improve the quality of life, LNG-IUS, a hormonal device, is recommended by NICE as first-line treatment for non-structural causes of HMB, such as endometrial hyperplasia, small fibroids (3cm), or adenomyosis. Patient satisfaction is crucial, as it influences treatment adherence. We conducted our study with the primary objective to evaluate continuation rate, expulsion rate, and satisfaction rate after levonorgestrel-releasing intrauterine system (LNG-IUS) insertion for HMB, aiming to promote LNG-IUS use.

This retrospective cohort study included women who had LNG-IUS inserted for heavy menstrual bleeding between June 2021 and September 2022. Based on a 6% discontinuation rate for LNG-IUS, a 95% confidence level, and a 5% alpha error, the required sample size was 85. Accounting for a 15% loss to follow-up, the final sample size was 98.

The response was measured in all 92 women who underwent hysterectomy or expelled the device before complete follow-up. 80/92 (91.3%) were satisfied with the treatment and would recommend it to women with similar complaints. At 12-month follow-up, women had a significant increase in their mean haemoglobin values from the baseline value of 9.35 ± 2.25 gm/dL to 10.4 ± 1.4 gm/dL, and this led to improvement in symptoms of anaemia as well.

LNG- IUS is highly effective in treating heavy menstrual bleeding without any major side effects; the success rate increases with good case selection. The results from the present study can be used to counsel patients with AUB. Similar content being viewed by others

NG88 N. Heavy Menstrual Bleeding: assessment and management National Institute for Health and Clinical Excellence (NICE) (2021) Perelló J, Tarruella JR, Calaf J. Sangrado menstrual abundante y su detección en la práctica clínica. Med Clin. 2021;157(7):332–8. https://doi.org/10.1016/j.medcli.2021.02.006. Davis E, Sparzak PB. Abnormal Uterine Bleeding. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532913. Long-Acting Reversible Contraception Implants and Intrauterine Devices. Practice Bulletin. Number 186.November 2017. Reaffirmed 2024 Wojcik N, Watkins L, Nugent R. Patient acceptability, continuation and complication rates with immediate postpartum levonorgestrel intrauterine device insertion at caesarean section and vaginal birth. Aust N Z J Obstet Gynaecol. 2022;62(5):773–8. https://doi.org/10.1111/ajo.13535. Shim JY, Ryan ME, Milliren CE, et al. Continuation rates of hormonal intrauterine devices in adolescents and young adults when placed for contraceptive and non-contraceptive indications. Contraception. 2024;129: 110304. https://doi.org/10.1016/j.contraception.2023.110304. Stovall DW, Aqua K, Römer T, Donders G, Sørdal T, Hauck B, et al. Satisfaction and continuation with LNG-IUS 12: findings from the real-world kyleena® satisfaction study. Eur J Contracept Reprod Health Care. 2021;26(6):462–72. Kumari A, Tirkey S, Prakash J. Effectiveness of levonorgestrel releasing intrauterine system in perimenopausal women with heavy menstrual bleeding: a prospective study at a teaching hospital in India. J Menopausal Med. 2022;28(3):128. Chen S, Liu J, Peng S, Zheng Y. LNG-IUS vs. medical treatments for women with heavy menstrual bleeding: a systematic review and meta-analysis. Front Med. 2022;9:948709. https://doi.org/10.3389/fmed.2022.948709. Rodriguez MB, Dias S, Jordan V, et al. Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis. Cochrane Database of Syst Rev. 2022;2023(2):CD013180. https://doi.org/10.1002/14651858.CD013180.pub2. Funding This is a secondary analysis of the study which received funding from AIIMS, Nagpur. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interest There is no conflict of interest among authors. Ethics approval All authors approved the manuscript and its submission to the journal. Ethical committee has approved this study. Consent for publication This manuscript has not been published and is not under consideration for publication in any other journal. Informed consent Informed consent was obtained from all individual participants included in the study. The participants have consented to the submission and publication of relevant data. Identifiable information has been omitted or anonymized to preserve confidentiality. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Avantika Gupta, MD, OBGY, Associate Professor; Neha Gangane, MD OBGY, Associate Professor; Bishnupriya Moharana, MBBS, Junior Resident; Minal Pradip Dhanvij, MS OBGY, Senior Resident; Medha Davile, MD OBGY, Associate Professor; Shuchita Mundle, MD OBGY, Professor and HOD. Rights and permissions About this article Cite this article Gupta, A., Gangane, N., Moharana, B. et al. Self-Reported Patient’s Continuation Rate, Complications, and Content (3c’s Study) with Levonorgestrel Intrauterine System (LNG-IUS) for Heavy Menstrual Bleeding. J Obstet Gynecol India 76, 272–275 (2026). https://doi.org/10.1007/s13224-025-02152-2 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s13224-025-02152-2